0001209191-20-017553.txt : 20200309
0001209191-20-017553.hdr.sgml : 20200309
20200309214535
ACCESSION NUMBER: 0001209191-20-017553
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200306
FILED AS OF DATE: 20200309
DATE AS OF CHANGE: 20200309
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hindson Benjamin J.
CENTRAL INDEX KEY: 0001786391
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39035
FILM NUMBER: 20699750
MAIL ADDRESS:
STREET 1: 10X GENOMICS, INC.
STREET 2: 6230 STONERIDGE MALL ROAD
CITY: PLEASANTON
STATE: CA
ZIP: 94588
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: 10x Genomics, Inc.
CENTRAL INDEX KEY: 0001770787
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 455614458
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6230 STONERIDGE MALL ROAD
CITY: PLEASANTON
STATE: CA
ZIP: 94588
BUSINESS PHONE: (925) 401-7300
MAIL ADDRESS:
STREET 1: 6230 STONERIDGE MALL ROAD
CITY: PLEASANTON
STATE: CA
ZIP: 94588
FORMER COMPANY:
FORMER CONFORMED NAME: 10X Genomics, Inc.
DATE OF NAME CHANGE: 20190315
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-03-06
0
0001770787
10x Genomics, Inc.
TXG
0001786391
Hindson Benjamin J.
C/O 10X GENOMICS, INC.
6230 STONERIDGE MALL ROAD
PLEASANTON
CA
94588
1
1
1
0
See Remarks
Class A Common Stock
2020-03-06
4
M
0
33750
0.88
A
101250
D
Class A Common Stock
2020-03-06
4
S
0
4788
62.8781
D
96462
D
Class A Common Stock
2020-03-06
4
S
0
8702
63.7843
D
87760
D
Class A Common Stock
2020-03-06
4
S
0
6200
64.849
D
81560
D
Class A Common Stock
2020-03-06
4
S
0
3816
65.7358
D
77744
D
Class A Common Stock
2020-03-06
4
S
0
2000
66.732
D
75744
D
Class A Common Stock
2020-03-06
4
S
0
1300
67.9569
D
74444
D
Class A Common Stock
2020-03-06
4
S
0
3099
69.1993
D
71345
D
Class A Common Stock
2020-03-06
4
S
0
3845
69.8396
D
67500
D
Stock Option (right to buy)
0.88
2020-03-06
4
M
0
33750
0.00
D
2025-10-27
Class A Common Stock
33750
348750
D
The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
This transaction was executed in multiple trades at prices ranging from $62.31 to $63.28. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $63.335 to $64.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $64.34 to $65.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $65.35 to $66.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $66.35 to $67.25. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $67.50 to $68.49. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $68.52 to $69.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $69.53 to $70.44. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
All of the shares subject to the option are fully vested and exercisable as of the date hereof.
Chief Scientific Officer and President
/s/ Eric S. Whitaker, as Attorney-in-Fact
2020-03-09